“[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab”, Radiol Oncol, vol. 54, no. 3, pp. 285–294, Sep. 2020, Accessed: Sep. 23, 2026. Available: https://www.radioloncol.com/index.php/ro/article/view/3452